Why are self-medication opportunities limited in Austria? An interview study and comparison with other countries
- PMID: 33493218
- PMCID: PMC7833129
- DOI: 10.1371/journal.pone.0245504
Why are self-medication opportunities limited in Austria? An interview study and comparison with other countries
Abstract
Background: Austria has high health resource use compared to similar countries. Reclassifying (switching) medicines from prescription to non-prescription can reduce pressure on health resources and aid timely access to medicines. Since Austria is less progressive in this area than many other countries, this research aimed to elucidate enablers and barriers to it reclassifying medicines and make recommendations for change in the context of similar research conducted elsewhere.
Methods: Qualitative research using a heuristic approach was conducted in Austria in 2018. Informed by their own "insider" and "outsider" knowledge, the authors identified themes from personal interviews with 24 participants, including reclassification committee members, government officials and stakeholders, before comparing these themes with earlier research findings.
Results: Significant barriers to reclassification included committee conservatism, minimal political support, medical negativity and few company applications. Insufficient transparency about committee decisions, expectations of adverse committee decisions and a limited market discouraged company applications. Austria's 'social partnership' arrangement and consensus decision making aided a conservative approach, but the regulator and an alternative non-committee switch process were enabling. Pharmacy showed mixed interest in reclassification. Suggested improvements include increasing transparency, committee composition changes, encouraging a more evidence-based approach by the committee, more pharmacy undergraduate clinical training, and companies using scientific advisory meetings and submitting high quality applications.
Conclusion: Removing barriers to reclassification would facilitate non-prescription availability of medicines and encourage self-care, and could reduce pressure on healthcare resources.
Conflict of interest statement
I have read the journal’s policy and the authors of this manuscript have the following competing interests: NG reports consultancy work on reclassification, and speaker and travel costs for IGEPHA; CB is employed by AGES, the medicines regulator, but has no other conflicts to report; SB has no conflicts to report. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
References
-
- Ostermann H, Renner A-T, Bobek J, Schneider P, Vogler S. A cost/benefit analysis of selfcare systems in the European Union. European Commission; 2015.
-
- Anonymous. [ÖGK Vice Huss warns of millions in deficit] ÖGK-Vize Huss warnt vor Defizit in Millionenhöhe Austria: Standard Verlagsgesellschaft mbH; 2020 [cited: 16 May 2020]. Available from: https://www.derstandard.at/story/2000117389441/oegk-vize-huss-warnt-vor-....
-
- Blenkinsopp A, Bond C. Over the counter medication. London: British Medical Association Board of Science; 2005.
-
- Bauer C, May U. Potentials and opportunities for OTC-switches in Austria. Vienna: Österreichische Apotheker-Verlagsgesellschaft m.b.H; 2018.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
